Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for Anemia in Cancer Patients Not Receiving Chemotherapy
NCT00083486Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Feb 2004
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anemia comparing Epoetin alfa Arm with Placebo Arm (2 arms). Primary endpoint: Hemoglobin level. Started Feb 2004; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00083486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083486.